Published in J Clin Invest on December 01, 2007
Continuous requirement for the TCR in regulatory T cell function. Nat Immunol (2014) 2.11
Programmed cell removal: a new obstacle in the road to developing cancer. Nat Rev Cancer (2011) 1.84
Identification of sample annotation errors in gene expression datasets. Arch Toxicol (2015) 1.68
Decreased expression of CD200 and CD200 receptor in Alzheimer's disease: a potential mechanism leading to chronic inflammation. Exp Neurol (2008) 1.44
The classification of microglial activation phenotypes on neurodegeneration and regeneration in Alzheimer's disease brain. Arch Immunol Ther Exp (Warsz) (2012) 1.23
Growth-inhibitory and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations. Neoplasia (2009) 1.23
A gene expression signature of invasive potential in metastatic melanoma cells. PLoS One (2009) 1.21
The immunosuppressive surface ligand CD200 augments the metastatic capacity of squamous cell carcinoma. Cancer Res (2010) 1.14
Tumor expression of CD200 inhibits IL-10 production by tumor-associated myeloid cells and prevents tumor immune evasion of CTL therapy. Eur J Immunol (2010) 1.00
Melanoma cell expression of CD200 inhibits tumor formation and lung metastasis via inhibition of myeloid cell functions. PLoS One (2012) 0.99
Somatic p16(INK4a) loss accelerates melanomagenesis. Oncogene (2010) 0.99
Endothelial CD200 is heterogeneously distributed, regulated and involved in immune cell-endothelium interactions. J Anat (2009) 0.94
Cure of metastatic growth of EMT6 tumor cells in mice following manipulation of CD200:CD200R signaling. Breast Cancer Res Treat (2013) 0.89
Metastasis in an orthotopic murine model of melanoma is independent of RAS/RAF mutation. Melanoma Res (2010) 0.87
Gold nanoparticle-mediated detection of circulating cancer cells. Clin Lab Med (2012) 0.86
Impact of MAPK Pathway Activation in BRAF(V600) Melanoma on T Cell and Dendritic Cell Function. Front Immunol (2013) 0.85
Aberrant CD200/CD200R1 expression and function in systemic lupus erythematosus contributes to abnormal T-cell responsiveness and dendritic cell activity. Arthritis Res Ther (2012) 0.84
Distribution and expression of CD200 in the rat respiratory system under normal and endotoxin-induced pathological conditions. J Anat (2010) 0.84
CD200 in CNS tumor-induced immunosuppression: the role for CD200 pathway blockade in targeted immunotherapy. J Immunother Cancer (2014) 0.82
The mojastin mutant Moj-DM induces apoptosis of the human melanoma SK-Mel-28, but not the mutant Moj-NN nor the non-mutated recombinant Moj-WN. Toxicon (2010) 0.81
Comparison of immunity in mice cured of primary/metastatic growth of EMT6 or 4THM breast cancer by chemotherapy or immunotherapy. PLoS One (2014) 0.79
Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy. Mol Oncol (2015) 0.79
Alternative splicing of CD200 is regulated by an exonic splicing enhancer and SF2/ASF. Nucleic Acids Res (2010) 0.78
The role of tumor expression of CD200 in tumor formation, metastasis and susceptibility to T lymphocyte adoptive transfer therapy. Oncoimmunology (2012) 0.78
Statistically invalid classification of high throughput gene expression data. Sci Rep (2013) 0.77
A Critical Role for CD200R Signaling in Limiting the Growth and Metastasis of CD200+ Melanoma. J Immunol (2016) 0.75
Over-Expression of CD200 Predicts Poor Prognosis in Cutaneous Squamous Cell Carcinoma. Med Sci Monit (2016) 0.75
A Truncated form of CD200 (CD200S) Expressed on Glioma Cells Prolonged Survival in a Rat Glioma Model by Induction of a Dendritic Cell-Like Phenotype in Tumor-Associated Macrophages. Neoplasia (2016) 0.75
Intragenic Variations in BTLA Gene Influence mRNA Expression of BTLA Gene in Chronic Lymphocytic Leukemia Patients and Confer Susceptibility to Chronic Lymphocytic Leukemia. Arch Immunol Ther Exp (Warsz) (2016) 0.75
Tumor-derived vaccines containing CD200 inhibit immune activation: implications for immunotherapy. Immunotherapy (2016) 0.75
Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet (2000) 24.22
BRAF mutation predicts sensitivity to MEK inhibition. Nature (2005) 17.14
The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science (1989) 16.54
Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science (1995) 16.19
Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity (1995) 14.90
A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat Genet (2003) 12.16
Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol (2006) 7.40
Progress in human tumour immunology and immunotherapy. Nature (2001) 6.97
Essential role for oncogenic Ras in tumour maintenance. Nature (1999) 6.51
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A (2003) 5.49
Down-regulation of the macrophage lineage through interaction with OX2 (CD200). Science (2000) 4.41
Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev (2006) 4.24
Cyclin encoded by KS herpesvirus. Nature (1996) 3.32
The gene expression signatures of melanoma progression. Proc Natl Acad Sci U S A (2005) 3.05
Vitiligo in patients with metastatic melanoma: a good prognostic sign. J Am Acad Dermatol (1983) 2.65
Characterization of the CD200 receptor family in mice and humans and their interactions with CD200. J Immunol (2003) 2.38
RNA expression analysis of formalin-fixed paraffin-embedded tumors. Lab Invest (2007) 2.25
Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity. J Immunother (2006) 1.75
Lack of extracellular signal-regulated kinase mitogen-activated protein kinase signaling shows a new type of melanoma. Cancer Res (2007) 1.62
Molecular mechanisms of CD200 inhibition of mast cell activation. J Immunol (2004) 1.57
Regulation of myeloid cell function through the CD200 receptor. J Immunol (2006) 1.56
Update on immunotherapy for melanoma. J Natl Compr Canc Netw (2006) 1.52
CD200 as a prognostic factor in acute myeloid leukaemia. Leukemia (2007) 1.49
Down-regulation of basophil function by human CD200 and human herpesvirus-8 CD200. J Immunol (2005) 1.47
CD200 is a new prognostic factor in multiple myeloma. Blood (2006) 1.44
Human herpesvirus 8 K14 protein mimics CD200 in down-regulating macrophage activation through CD200 receptor. J Virol (2004) 1.38
Production of IL-10 by melanoma cells: examination of its role in immunosuppression mediated by melanoma. Int J Cancer (1994) 1.35
CD200 is a ligand for all members of the CD200R family of immunoregulatory molecules. J Immunol (2004) 1.33
The RNA subunit of telomerase is encoded by Marek's disease virus. J Virol (2003) 1.32
Immunity to melanoma antigens: from self-tolerance to immunotherapy. Adv Immunol (2006) 1.31
Antibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immunomodulation. Proc Natl Acad Sci U S A (2006) 1.28
Enhanced survival associated with vitiligo expression during maintenance biotherapy for metastatic melanoma. J Invest Dermatol (2006) 1.26
Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma. Cancer Immunol Immunother (2003) 1.21
Myxoma virus M141R expresses a viral CD200 (vOX-2) that is responsible for down-regulation of macrophage and T-cell activation in vivo. J Virol (2005) 1.20
The CD200 receptor is a novel and potent regulator of murine and human mast cell function. J Immunol (2005) 1.15
Therapeutic implications of autoimmune vitiligo T cells. Autoimmun Rev (2006) 1.12
Use of retrovirus expression of interfering RNA to determine the contribution of activated K-Ras and ras effector expression to human tumor cell growth. Methods Enzymol (2006) 1.11
The human T cell response to melanoma antigens. Adv Immunol (2006) 1.05
Neuronal/lymphoid membrane glycoprotein MRC OX-2 is a member of the immunoglobulin superfamily with a light-chain-like structure. Biochem Soc Symp (1986) 1.02
Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 replication and transcription activator regulates viral and cellular genes via interferon-stimulated response elements. J Virol (2005) 1.02
Management of metastatic melanoma 2005. Surg Oncol Clin N Am (2006) 0.97
Strategies for the development of more effective adjuvant therapy of melanoma: current and future explorations of antibodies, cytokines, vaccines, and combinations. Clin Cancer Res (2006) 0.93
Production of multiple cytokines by cultured human melanomas. Exp Dermatol (1993) 0.89
Advances in specific immunotherapy of malignant melanoma. J Am Acad Dermatol (2000) 0.81
Melanoma cells interfere with the interaction of dendritic cells with NK/LAK cells. Int J Cancer (2006) 0.79
Tensional homeostasis and the malignant phenotype. Cancer Cell (2005) 19.30
Stem-cell ageing modified by the cyclin-dependent kinase inhibitor p16INK4a. Nature (2006) 9.20
p16INK4a induces an age-dependent decline in islet regenerative potential. Nature (2006) 9.09
The regulation of INK4/ARF in cancer and aging. Cell (2006) 8.75
Ink4a/Arf expression is a biomarker of aging. J Clin Invest (2004) 8.30
Increasing p16INK4a expression decreases forebrain progenitors and neurogenesis during ageing. Nature (2006) 8.06
LKB1 modulates lung cancer differentiation and metastasis. Nature (2007) 7.80
Loss of the Lkb1 tumour suppressor provokes intestinal polyposis but resistance to transformation. Nature (2002) 6.10
The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell (2006) 5.34
Circular RNAs are abundant, conserved, and associated with ALU repeats. RNA (2012) 5.16
Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biol (2003) 5.14
Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. Cancer Cell (2002) 5.11
Ena/VASP proteins: regulators of the actin cytoskeleton and cell migration. Annu Rev Cell Dev Biol (2003) 4.22
Expression of linear and novel circular forms of an INK4/ARF-associated non-coding RNA correlates with atherosclerosis risk. PLoS Genet (2010) 3.89
Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell (2012) 3.77
Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors. Cancer Cell (2010) 3.40
A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature (2012) 3.24
Survival differences between patients with scalp or neck melanoma and those with melanoma of other sites in the Surveillance, Epidemiology, and End Results (SEER) program. Arch Dermatol (2008) 3.11
Monitoring tumorigenesis and senescence in vivo with a p16(INK4a)-luciferase model. Cell (2013) 3.04
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med (2015) 3.00
Arp2/3 is critical for lamellipodia and response to extracellular matrix cues but is dispensable for chemotaxis. Cell (2012) 2.98
L-Selectin(hi) but not the L-selectin(lo) CD4+25+ T-regulatory cells are potent inhibitors of GVHD and BM graft rejection. Blood (2004) 2.90
INK4/ARF transcript expression is associated with chromosome 9p21 variants linked to atherosclerosis. PLoS One (2009) 2.77
Using mechanobiological mimicry of red blood cells to extend circulation times of hydrogel microparticles. Proc Natl Acad Sci U S A (2011) 2.63
Coronin 1B coordinates Arp2/3 complex and cofilin activities at the leading edge. Cell (2007) 2.59
Mouse model for noninvasive imaging of HIF prolyl hydroxylase activity: assessment of an oral agent that stimulates erythropoietin production. Proc Natl Acad Sci U S A (2005) 2.54
Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc Natl Acad Sci U S A (2014) 2.46
Coronin 1B antagonizes cortactin and remodels Arp2/3-containing actin branches in lamellipodia. Cell (2008) 2.28
New insights into the regulation and cellular functions of the ARP2/3 complex. Nat Rev Mol Cell Biol (2012) 2.25
RNA expression analysis of formalin-fixed paraffin-embedded tumors. Lab Invest (2007) 2.25
In vitro-differentiated TH17 cells mediate lethal acute graft-versus-host disease with severe cutaneous and pulmonary pathologic manifestations. Blood (2008) 2.24
Expression of p16(INK4a) in peripheral blood T-cells is a biomarker of human aging. Aging Cell (2009) 2.21
Somatic LKB1 mutations promote cervical cancer progression. PLoS One (2009) 2.21
Engineering and selection of shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles. Mol Ther (2008) 2.19
P-Rex1 is required for efficient melanoblast migration and melanoma metastasis. Nat Commun (2011) 2.18
Mouse reporter strain for noninvasive bioluminescent imaging of cells that have undergone Cre-mediated recombination. Mol Imaging (2003) 2.17
Leukocyte migration and graft-versus-host disease. Blood (2005) 2.17
Expression of p16(INK4a) prevents cancer and promotes aging in lymphocytes. Blood (2011) 2.16
Acrodermatitis enteropathica-like eruption and failure to thrive as presenting signs of cystic fibrosis. J Am Acad Dermatol (2006) 2.05
VHL promotes E2 box-dependent E-cadherin transcription by HIF-mediated regulation of SIP1 and snail. Mol Cell Biol (2006) 2.03
Constitutive telomerase expression promotes mammary carcinomas in aging mice. Proc Natl Acad Sci U S A (2002) 2.03
Coronins: the return of the crown. Trends Cell Biol (2006) 2.02
Regulation of endocytosis via the oxygen-sensing pathway. Nat Med (2009) 2.00
The actin regulator coronin 1A is mutant in a thymic egress-deficient mouse strain and in a patient with severe combined immunodeficiency. Nat Immunol (2008) 1.97
Effect of cytotoxic chemotherapy on markers of molecular age in patients with breast cancer. J Natl Cancer Inst (2014) 1.96
Preformed antibody, not primed T cells, is the initial and major barrier to bone marrow engraftment in allosensitized recipients. Blood (2006) 1.92
Cancer: crime and punishment. Nature (2005) 1.91
Critical role for CCR5 in the function of donor CD4+CD25+ regulatory T cells during acute graft-versus-host disease. Blood (2005) 1.89
BRAF and NRAS mutations in melanoma and melanocytic nevi. Melanoma Res (2006) 1.85
Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib. Proc Natl Acad Sci U S A (2004) 1.85
A cell-based assay for aggregation inhibitors as therapeutics of polyglutamine-repeat disease and validation in Drosophila. Proc Natl Acad Sci U S A (2003) 1.84
TLR agonists regulate alloresponses and uncover a critical role for donor APCs in allogeneic bone marrow rejection. Blood (2008) 1.82
CHIP deficiency decreases longevity, with accelerated aging phenotypes accompanied by altered protein quality control. Mol Cell Biol (2008) 1.82
Critical roles of phosphorylation and actin binding motifs, but not the central proline-rich region, for Ena/vasodilator-stimulated phosphoprotein (VASP) function during cell migration. Mol Biol Cell (2002) 1.81
Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy. J Natl Cancer Inst (2012) 1.81
A human breast cell model of preinvasive to invasive transition. Cancer Res (2008) 1.79
In vivo imaging of graft-versus-host-disease in mice. Blood (2004) 1.78
PEGylated PRINT nanoparticles: the impact of PEG density on protein binding, macrophage association, biodistribution, and pharmacokinetics. Nano Lett (2012) 1.77
Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer. J Clin Oncol (2011) 1.75
Mitigation of hematologic radiation toxicity in mice through pharmacological quiescence induced by CDK4/6 inhibition. J Clin Invest (2010) 1.74
Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer models. Clin Cancer Res (2012) 1.74
An intact NEDD8 pathway is required for Cullin-dependent ubiquitylation in mammalian cells. EMBO Rep (2002) 1.71
Autocrine laminin-5 ligates alpha6beta4 integrin and activates RAC and NFkappaB to mediate anchorage-independent survival of mammary tumors. J Cell Biol (2003) 1.67
Separation of graft-versus-host disease from graft-versus-leukemia responses by targeting CC-chemokine receptor 7 on donor T cells. Blood (2010) 1.66
Lack of extracellular signal-regulated kinase mitogen-activated protein kinase signaling shows a new type of melanoma. Cancer Res (2007) 1.62
ARF functions as a melanoma tumor suppressor by inducing p53-independent senescence. Proc Natl Acad Sci U S A (2007) 1.61
State of the science: an update on renal cell carcinoma. Mol Cancer Res (2012) 1.58
Phosphorylation of coronin 1B by protein kinase C regulates interaction with Arp2/3 and cell motility. J Biol Chem (2005) 1.58
F-actin binding is essential for coronin 1B function in vivo. J Cell Sci (2007) 1.55
Targeted ethnography as a critical step to inform cultural adaptations of HIV prevention interventions for adults with severe mental illness. Soc Sci Med (2007) 1.55
HIF2alpha cooperates with RAS to promote lung tumorigenesis in mice. J Clin Invest (2009) 1.49
LKB1/STK11 inactivation leads to expansion of a prometastatic tumor subpopulation in melanoma. Cancer Cell (2012) 1.49
The "Fringe Sign" - A useful clinical finding in traction alopecia of the marginal hair line. Dermatol Online J (2011) 1.48
pVHL acts as an adaptor to promote the inhibitory phosphorylation of the NF-kappaB agonist Card9 by CK2. Mol Cell (2007) 1.47
Contribution of Ena/VASP proteins to intracellular motility of listeria requires phosphorylation and proline-rich core but not F-actin binding or multimerization. Mol Biol Cell (2002) 1.47
Differential roles for CCR5 expression on donor T cells during graft-versus-host disease based on pretransplant conditioning. J Immunol (2004) 1.44
A mouse model of human oral-esophageal cancer. J Clin Invest (2002) 1.40
p38MAPK controls expression of multiple cell cycle inhibitors and islet proliferation with advancing age. Dev Cell (2009) 1.40
Overexpression of collagenase 1 (MMP-1) is mediated by the ERK pathway in invasive melanoma cells: role of BRAF mutation and fibroblast growth factor signaling. J Biol Chem (2004) 1.39
Sequential high-dose ifosfamide, carboplatin and etoposide with rituximab for relapsed Hodgkin and large B-cell non-Hodgkin lymphoma: increased toxicity without improvement in progression-free survival. Leuk Lymphoma (2009) 1.38
Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. J Clin Invest (2014) 1.38
HMGA2, microRNAs, and stem cell aging. Cell (2008) 1.38
Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma. J Clin Oncol (2010) 1.37
Review: a meta-analysis of GWAS and age-associated diseases. Aging Cell (2012) 1.36
Nanoparticle clearance is governed by Th1/Th2 immunity and strain background. J Clin Invest (2013) 1.36
Melanoma cells show a heterogeneous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of B-RAF with PLX-4032. Radiother Oncol (2011) 1.35
RKIP downregulates B-Raf kinase activity in melanoma cancer cells. Oncogene (2005) 1.35